Boston-based Dana-Farber Cancer Institute (DFCI) entered into a collaborative agreement with an Australian oncology-focused biotech called Kazia Therapeutics Limited (ASX: […]
The Benderson family of Sarasota, Florida, donated $5 million to the Dana-Farber Cancer Institute in Boston, MA, representing the largest […]
Patients with acute or chronic graft-versus-host disease (GVHD) have several unmet needs, including later-line therapies. Novel agents and other research […]
William G. Kaelin, Jr. MD won the 2019 Nobel Prize in medicine. His research findings at Dana-Farber are game-changing: a […]
Young Dana-Farber investigators Jennifer Guerriero, PhD and Sarah Hill, MD, PhD are on a mission to find better treatments for […]
A surge of clinical trials with great potential for promising new treatments for T-cell lymphoma are based on significant basic […]
The Dana-Farber Cancer Institute has received a $5 million gift from the Edward P. Evans Foundation in support of research […]
ImaginAB Inc., a Los Angeles-based, immune-oncology imaging company focused on offering actionable insight into patient selection and treatment for cancer […]
Dana-Farber Cancer Institute’s Guru P Sonpavde explains what clinical trials are and who they may be appropriate for. Dr. Sonpavde, […]
Science Daily reports that Dana-Farber Cancer Institute researchers have discovered a previously unknown molecular vulnerability in two rare, aggressive and […]
